|Day Low/High||77.53 / 78.09|
|52 Wk Low/High||67.88 / 92.85|
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
It's time to unload these toxic stocks from your portfolio.
Shares of biotech micro-cap Cyclacel Pharmaceuticals have doubled in price in the past 10 days. Call it the Lloyd Christmas effect.
AZD3293 is an oral potent small molecule BACE inhibitor in phase 3 development
Jim Cramer ponders how the playing field is being leveled and how three stocks indicate a change in interest rates.
Johnson & Johnson, American Electric Power and Federal Realty say rates are going higher.
Be aware that Johnson & Johnson, American Electric Power and Federal Realty don't roll over idly.
Earlier this month the two major pharmacy benefit managers, CVS Caremark CVS and Express Scripts ESRX released lists of drugs they will no longer cover in 2017.
The Dublin-based drugmaker has some 65-plus mid-to-late stage assets in its pipeline.
Documentary chronicles the journey of two Canine Assistants recipients as they develop unbreakable bonds with their dogs
The market action looks very much like it did before the drops that occurred in 2000 and 2008.
Jim Cramer says Eli Lilly has been overpromising and underdelivering.
I'm not inclined to make market calls, but the action on my screen is pushing me to a defensive stance.
If buyers don't appear around $78 then a deeper correction is likely.
Trade-Ideas LLC identified Eli Lilly and (LLY) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Investors brace for the first cut - or change - in central bank interest rates in more than seven years.
The big bounce in Biogen's valuation over the past month would likely bake in a good chunk of the upside premium that could come from any takeover offer.
Stocks with insider trader activity include LLY, KFS and TILE
Facebook continued to reap the rewards of its strong quarterly results today.
Eli Lilly (LLY) current CEO John Lechleiter steps down and new CEO David Ricks shares his plans for the company.
The pharmaceutical giant tapped a 20-year company veteran to succeed John Lechleiter, who will retire as president and CEO at yearend.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
Eli Lilly (LLY) announced the resignation of CEO John Lichleiter at the end of 2016.
A TauRx Therapeutics drug designed to dissolve tangles of a protein called tau in the brain failed to slow cognitive and functional declines of Alzheimer's patients compared with a control.